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When I heard the learn’d astronomer,  
When the proofs, the figures, were ranged in columns before me,  
When I was shown the charts and diagrams, to add, divide, and measure them,  
When I sitting heard the astronomer where he lectured with much applause in the lecture-room,  
How soon unaccountable I became tired and sick,  
Till rising and gliding out I wander’d off by myself,  
In the mystical moist night-air, and from time to time,  
Look’d up in perfect silence at the stars. 
Walt Whitman
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ABSTRACT 
Skeletal muscle is remarkable in its ability to adjust to our needs. It can change its energy 
stores and usage, as well as its total mass. Furthermore, skeletal muscle adapts to deactivate 
reactive oxygen species produced, which in turn can both damage cells and convey signals. 
The molecular mechanisms regulating skeletal muscle plasticity are many, including reactive 
oxygen species, AMPK, and FOXO. AMPK functions as a molecular energy sensor, while the 
FOXO proteins are transcription factors that bind to the DNA, and regulate gene transcription. 
To understand the role of reactive oxygen species in health, we investigated how an 
intravenous antioxidant infusion of N-acetyl-cysteine (NAC), affected exercise-modulated 
insulin sensitivity. We found that NAC infusion decreased whole-body insulin sensitivity and 
skeletal muscle p70S6K phosphorylation, indicating diminished glucose uptake and attenuated 
protein synthesis.  
We also investigated the changes occurring in the atrophying skeletal muscle of individuals 
with spinal cord injury.  We find that AMPK signaling decreases during the first year after 
injury, and that protein content of the AMPK regulatory γ1 subunit decreased, and γ3 increased. 
Skeletal muscle energy metabolism decreased during the first year after spinal cord injury, as 
indicated by the decreased protein content of the mitochondrial respiration complexes I-III. 
The contractile myosin heavy chain proteins myosin heavy chain 1 declined, and myosin heavy 
chain IIa increased 12 months after spinal cord injury.  
In order to understand how the changes in energy metabolizing and contractile proteins 
occurred, we investigated the mechanisms mediating protein degradation and synthesis, 
namely translation, autophagy and proteasomal degradation. We found that protein content of 
LC3II, as well as protein content and phosphorylation of S6 kinase, increased transiently during 
the first year after injury, indicating a temporary increase in autophagy and protein synthesis. 
We also detected stably increased levels of Lys48 poly-ubiquitinated proteins, indicating 
constantly increased proteasomal degradation during the first year after injury. 
Additionally, FOXO3 protein content, and FOXO1 phosphorylation decreased during the 
first year after spinal cord injury. To better understand the metabolic role of FOXO proteins, 
we transfected mouse skeletal muscle with FOXO proteins modified to bind to the DNA 
without activating transcription, leading to inhibited expression of FOXO regulated genes. We 
find that inhibition FOXO transcriptional activity decreased skeletal muscle glucose uptake, 
and increased inflammatory signaling and immune cell infiltration.  
Together, these studies partly elucidate how skeletal muscle adapts to its changing 
environment. We find that reactive oxygen species appear to be involved in the beneficial 
effects of exercise, and we unravel the signals and mechanisms mediating decreased skeletal 
muscle mass after spinal cord injury. Finally, we find that FOXO proteins directly affect gene 
networks involved in regulating inflammation and glucose metabolism in skeletal muscle. 
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1 INTRODUCTION 
Skeletal muscle is a remarkable organ without which metazoan life would be not be 
recognizable today. The main role of skeletal muscle is locomotion, but its functions span far 
beyond. It is becoming increasingly clear that it has an essential role as an endocrine organ, 
both by regulating energy metabolism, and by secreting hormones. Skeletal muscle accounts 
for approximately 40% of total body mass, consumes about 30% of our basal metabolic rate 
[1], absorbs ~30% of postprandial glucose [2], while accounting for ~80% of insulin stimulated 
glucose uptake [3].  
Skeletal muscle is a remarkably plastic organ. Exercise can increase muscle mass 
dramatically, and alters function by changing expression of energy metabolizing enzymes, 
mitochondrial density, vascularization, and myofiber nucleation. On the other end of the 
spectrum, inactivity, disease, and spinal cord injury lead to changes in fiber type distribution, 
and energy metabolizing enzymes in skeletal muscle. 
Furthermore, skeletal muscle is a primary site of insulin resistance in people with type 2 
diabetes. Loss of skeletal muscle mass (skeletal muscle atrophy) is debilitating both in terms 
of life quality due to reduced mobility and longevity due to weakened metabolic health. The 
role of skeletal muscle in endocrine health is manifold. It functions as a storage site for glucose 
and amino acids, and its storage capacity is vital for buffering energy abundance and shortage. 
Perturbations in energy storage are one of the root causes of today’s global obesity and health 
crisis. Moreover skeletal muscle functions also as an endocrine organ by secreting systemic 
and local myokines necessary for whole-body metabolic health.  
1.1 SKELETAL MUSCLE STRUCTURE AND METABOLISM. 
1.1.1 Structure and fiber types 
Skeletal muscle is composed of muscle fibers, with each fiber containing several myofibrils 
supported by a single muscle cell. The myofibrils are further subdivided into the most basic 
repeating unit of the skeletal muscle organ: the sarcomere. The sarcomere is defined as the 
structure between two Z lines, and is the structure responsible for force generation by the 
sliding of thick myosin filaments across thin actin filaments (reviewed in [4]). 
Human skeletal muscle fibers are subcategorized into three types based on their contractile 
and molecular properties: type I, type IIa, and type IIx fibers. Rodent skeletal muscle fibers 
have an additional fiber type denoted type IIb. The fiber type classification is based on several 
parameters including shortening velocity, myosin ATPase activity, or myosin heavy chain 
composition. 
Type I fibers, also called slow-twitch fibers, contract relatively slowly, are slow to fatigue, 
contain the slow isoform of myosin, myosin heavy chain I (MHC-I), and have a predominantly 
oxidative metabolism mediated through high mitochondrial density. Furthermore, they 
demonstrate high insulin sensitivity and high rate of glucose uptake, and are rich in myoglobin 
giving them a red color. 
Type IIa fibers, also called fast-twitch fibers, have intermediate features with both oxidative 
and glycolytic metabolism. They contract relatively fast, have intermediate fatigue time, and 
express myosin heavy chain IIa (MHC-IIa). Type IIa fibers are poor in myoglobin giving them 
a white appearance. 
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Type IIx, also referred to as fast-twitch fibers, have the fastest contractile speed of all human 
muscle fibers by expressing myosin heavy chain IIx (MHC-IIx), and their low mitochondrial 
density leads them to metabolize glucose, predominantly through glycolysis. Furthermore they 
express low levels of the facilitative glucose transporter subtype 4 (GLUT4) and have the 
lowest insulin sensitivity. As in the Type IIa fibers they have little myoglobin giving them a 
light color.  
The molecular and phenotypic properties correlate well with the observations that endurance 
athletes have a higher proportion of oxidative type I fibers and a high rate of whole-body 
glucose disposal [5], while patients with type 2 diabetes have a relative lower proportion of 
type I fibers and a relative higher proportion of type IIx fibers, concomitant with an impaired 
lower whole-body glucose disposal [6, 7]. Furthermore, skeletal muscle plasticity extends to 
fiber type distribution, and takes different forms depending on the external stimuli. Fasting [8], 
sepsis [9] and glycocorticoid administration [10] affect mainly slow-twitch fibers, while 
immobilization [11], unloading (both experimental and through microgravity exposure [12]), 
and spinal cord injury affect fast-twitch fibers [13]. 
1.1.2 Whole-body glucose homeostasis 
Whole-body glucose homeostasis is mediated through the reciprocal regulatory action of 
insulin and glucose, as well as glucagon, cortisol and adrenalin. Increased glucose levels in the 
blood stream lead to increased insulin secretion, which in turn leads to the absorption of glucose 
into skeletal muscle, liver, and adipose tissue. Insulin has several additional effects, including 
increased glycogen synthesis in liver and muscle, as well as an anabolic role by increasing 
protein synthesis. Insulin-induced absorption of blood glucose leads to suppression of insulin 
secretion from the pancreas due to reduced blood glucose levels. 
1.1.3 Glucose uptake 
Skeletal muscle glucose uptake is a tightly regulated process. Insulin binding to the insulin 
receptor leads to phosphorylation of the insulin receptor substrate 1, which recruits and 
activates phosphoinositide 3 kinase (PI3K) to the cell surface [14]. PI3K recruits both protein 
kinase B (Akt) and phosphoinositide-dependent kinase-1 (PDK1) [15] to the cell membrane, 
where PDK1 and mechanistic target of rapamycin (mTOR) complex 2 (mTORC2) 
phosphorylate Akt on different sites, an activating phosphorylation. Fully activated Akt leads 
to phosphorylation and inhibition of TBC1 domain family member 4 (TBC1D4) [16] and 
TBC1D1 [17]. TBC1D1/4 function as GTPase activating proteins (GAP), inhibiting the small 
monomeric GTP proteins of the Rab and Rac family. GAP inhibition leads to activation of Rab 
and Rac proteins, and translocation of GLUT4 containing vesicles to the plasma membrane, 
thereby increasing glucose transport into the cell [18]. 
In addition to insulin, skeletal muscle contraction by itself increases GLUT4 surface content 
and glucose uptake. Insulin and muscle contraction induce GLUT4 translocation to the cell 
membrane by modulating TBC1D1/4 [19]. Furthermore, skeletal muscle contraction increases 
glucose uptake both independently and synergistically with insulin [20, 21] through the 
activation of AMP-activated kinase (AMPK) [22] and other mechanisms [23, 24]. The high 
energy demands of contracting skeletal muscle alter energy balance by increasing both glucose 
uptake and utilization locally. Systemically, skeletal muscle contraction affects energy 
homeostasis by mobilizing stored energy depots throughout the body, and stimulating the 
secretion of myokines that shift homeostasis to the specific organismal needs. 
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1.1.4 Glucose metabolism 
Once glucose is transported across the skeletal muscle cell membrane, it has two major fates 
depending on the energy status of the myocyte. If energy supply is abundant, glucose enters 
the glycogenesis pathway and becomes polymerized to glycogen. In situations of energy 
demand, such as during exercise, glucose will be oxidized. Glucose oxidation is achieved by 
three interwoven enzymatic processes: glycolysis, the tricarboxylic acid (TCA, also known as 
Krebs, or citric acid cycle), and oxidative phosphorylation. Together these processes generate 
ATP and NADH. 
Glycolysis, the first step in glucose metabolism, is the least efficient of the three metabolic 
cascades in terms of ATP production (summarized in figure 1). At the same time, the products 
of glycolysis are essential for subsequent energy production steps. Glycolytic degradation of 
glucose is achieved through 10 discrete steps, with hexokinase catalyzing the first (and rate 
limiting) step, and pyruvate kinase the last step. The Krebs cycle consumes pyruvate generated 
in glycolysis, and converts it into among other things NADH. Finally the oxidative 
phosphorylation cascade utilizes the NADH produced in previous steps to generate a proton 
motive force across the inner mitochondrial membrane. The proton motive force is generated 
by the shuttling of electrons through complex I-IV, coupled to translocation of H+ towards 
Figure 1. Schematic representation of cellular energy metabolism. Dashed arrow indicates multistep cascade not 
shown here, molecules are not scale. Glucose is taken up by glucose transporters (GLUT1 as purple enzyme, GLUT4 
crystal structure not elucidated), and enters glycolysis (green) which through a multistep pathway generates NADH, 
ATP and pyruvate. Pyruvate is utilized in the citric acid cycle (TCA, blue) and generate additional NADH. The 
oxidative phosphorylation enzymes (OXPHOS in gray) generate a proton gradient by consuming NADH in the 
respirasome (CI, CIII, CIV). The ATPase utilizes the proton gradient to generate ATP from ADP. PDB files to 
generate figures where: 4pyp, 1eaa, 2nzt, 2h88, 3j9u. TCA cycle, and Pyruvate kinase where from 
http://pdb101.rcsb.org/ and used with permission. 
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inner membrane, which is finally utilized in the rotating [25] ATPase complex V to generate 
ATP. 
In situations of energy abundance, glucose is metabolized in non-oxidative (and thus 
reversible) pathways, and is also polymerized to glycogen. Glycogen is synthesized through 
the action of glycogen synthase (GS), which in turn is inhibited through phosphorylation by 
glycogen synthase kinase (GSK) under regulation of Akt. 
1.2 REACTIVE OXYGEN SPECIES 
1.2.1 Reactive oxygen species generation and deactivation 
Aerobic exercise profoundly increases oxidative metabolism, which has the potential to 
damage macromolecules by generating reactive free radical (e.g. OH., O2
-, & NO.) [26]. 
Consequently, living organisms have evolved enzymes that neutralize free radicals. Reactive 
oxygen species are generated by NADPH oxidases, peroxisomal metabolism, 
cyclooxygenases, and by “leakage” of electrons from the oxidative phosphorylation cascade. 
The vast majority of reactive oxygen species is generated from the latter, and specifically the 
oxidative phosphorylation cascade complex I and III. Reactive oxygen species are inactivated 
by several enzymatic cascades. The most reactive oxygen species, the superoxide anion O2
.-, is 
converted to H2O2, a less reactive oxygen species by superoxide dismutase (SOD). The fate of 
H2O2 is decided by the enzyme responsible for their full inactivation: symmetrical cleavage to 
H2O by catalase, thioredoxin oxidation by peroxidase, or glutathione (GSH) oxidation by 
glutathione peroxidase yielding GSSG and H2O. 
1.2.2 Reactive oxygen species in skeletal muscle health 
Reactive oxygen species are both detrimental and necessary for metabolic health. Animal 
models show that interference with the enzymes involved in inactivation of reactive oxygen 
species lead to several complications: knocking out glutathione peroxidase-1 in mice leads to 
increased insulin sensitivity only after exercise [27], while glutathione peroxidase 4 knockout 
mice are embryonically lethal [28]. Knockout mice lacking superoxide dismutase in the 
mitochondria display perinatal lethality [29], while mice lacking cytosolic superoxide 
dismutase appear normal but have decreased survival time in an hyperoxic environment [30]. 
There is an unfounded perception in the general public that antioxidant supplementation is 
beneficial to health. In reality, several studies show that antioxidant treatments appear to have 
either detrimental, or no effects on human health. Notably, two independent large scale double 
blind placebo studies investigating the effects of β-carotene supplementation in smokers found 
increased risk of lung cancer and mortality [31, 32]. The effects of antioxidant supplementation 
in skeletal muscle glucose uptake are again contradictory: 4 weeks of vitamin E and C 
supplementation has been shown to blunt training-induced increases in insulin sensitivity and 
expression of genes responsive to exercise [33]. Conversely, 12 weeks of vitamin E and C 
supplementation has been shown to be without effect on training-induced improvements on 
glucose infusion rate [26]. While there is evidence of increased oxidative stress in individuals 
with insulin resistance [34], a meta-analysis of 14 studies investigating the effects of 
antioxidant supplementation on fasting blood glucose or insulin levels showed no beneficial 
effects [35]. 
Hormesis is a conceptually attractive explanation for the observation that antioxidant 
supplementation is not beneficial while endogenous antioxidant defenses are necessary. 
Hormesis suggests that an organism’s beneficial or deleterious response to a substance is dose 
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dependent. Put in another way, a small amount of reactive oxygen species might be beneficial 
for metabolic health through changed signaling, while a larger dose might be detrimental 
through increased damage. Understanding how endogenously generated reactive oxygen 
species affect signaling cascades, will aid in further elucidating their role both as stressors and 
signaling molecules. 
1.3 SKELETAL MUSCLE MASS REGULATION 
Skeletal muscle mass is regulated by the balance between protein anabolism and catabolism. 
The anabolic arm of protein regulation revolves around translational regulation, while catabolic 
regulation involves protein ubiquitination, and proteosomal and autophagic degradation. 
Protein breakdown is essential for maintaining proper skeletal muscle function. Several 
conditions lead to skeletal muscle atrophy including aging (termed sarcopenia), cancer-induced 
cachexia, and spinal cord injury. The molecular mechanisms underlying the skeletal muscle 
atrophy induced by these conditions are probably related, but surely not identical. 
1.3.1 Signaling and effectors of muscle anabolism 
While the insulin signaling pathways described in section 1.1.3 regulates mainly glucose 
metabolism, the IGF1/IRS1/PI3K/Akt signaling axis integrates anabolic and catabolic arms of 
protein homeostasis. Central to control of translation, is the mTOR complex 1 (mTORC1). 
mTOR was first identified as a target of the bacterial macrolide rapamycin, leading to inhibition 
of cell proliferation and immune-responses. mTOR association with, among others, raptor 
forms mTORC1, while association with Rictor forms mTORC2.  mTORC1 is partly regulated 
by a GTPase complex composed of tuberous sclerosis factor 1 and 2 (TSC1 and TSC2). 
Activated TSC2-TSC1 complex regulates mTORC1 activity by regulating the small 
monomeric G-protein Rheb. GTP bound Rheb stimulates mTORC1 activity, and the TSC2-
TSC1 complex converts bound GTP into GDP, and thus inhibits Rheb. TSC2 takes input from 
several different signaling axis, including AMPK and Akt. AMPK phosphorylates TSC2, 
stimulating its GTPase activity [36], and leading to inhibition of mTORC1 activity. Akt 
phosphorylates TSC2 on a seperate residue, leading to more GTP being bound to Rheb, and 
stimulation of mTORC1 activity [37]. mTOR is further regulated by p70 S6 kinase (p70S6K) 
mediated phosphorylation on Ser2448 [38]. Finally, AMPK also phosphorylates raptor, and 
further inhibits mTORC1 activity and protein translation [39] (summarized in figure 2). 
mTORC1 phosphorylates and regulates 4E-BP1 and p70S6K. 4E-BP1 inhibits protein 
translation by blocking ribosomal binding to the mRNA chain. 4E-BP1 phosphorylation leads 
to dissociation from the mRNA chain, and decreased translational inhibition. Concurrent with 
4E-BP1 phosphorylation, mTORC1 activation phosphorylates p70S6K, which in turn activates 
the ribosomal 6 subunit (S6), regulating ribosomal biogenesis [40]. Increased phosphorylation 
and protein content of p70S6K, and S6, is a useful proxy for interrogating signals increasing 
protein synthesis. Conversely increased phosphorylation of 4E-BP1 indicates decreased protein 
translation, while decreased protein content of 4E-BP1 can indicate decreased expression of 
translational machinery. 
1.3.2 Signaling and effectors of muscle catabolism 
Protein degradation is necessary not only for muscle mass reduction, but also for overall 
metabolic health. Protein degradation is mediated by four main pathways: autophagy, 
proteasomal, caspases and calpains. Inhibition of either proteasomal [41] or autophagosomal 
[42] degradation leads to decreased skeletal muscle growth due to dysfunction, and insulin 
resistance [43]. Furthermore, exercise increases proteasomal and autophagic degradation in 
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humans [44], further highlighting the importance of protein turnover in health. While the 
majority of cellular proteins are degraded by the proteasomal degradation pathway [45], 
autophagy is also partly involved in skeletal muscle atrophy [46].Much less is known about 
caspases and Ca2+ dependent proteolytic degradation. Both calpains and caspases are thought 
to be involved in the initial acto-myosin degradation step [47, 48], and work in conjunction 
with the autophagic and proteasomal degradation pathway. 
Proteolysis by the 26S proteasome is surprisingly (due to the high energy in the peptide 
bond), ATP-dependent. The 26S proteasome consists of the catalytic 20S complex and the 19S 
ATPase-containing complex. The 20S subunit is further composed of the structural α subunits, 
and the catalytic β subunits. The barrel shaped 20S complex incorporates the peptide to be 
degraded, and nucleophilic [49] residues hydrolyze the peptide chain into smaller peptide 
fragments. The 26S proteasome is important for muscle atrophy as illustrated by the fact that 
proteasomal inhibitors attenuate denervation-induced skeletal muscle atrophy [50], and that 
expression of proteasomal α subunits are upregulated after spinal cord injury [51, 52]. 
Autophagy (from the greek αὐτόφαγος - self-eater) can further be subdivided into macro-, 
micro- or chaperone-mediated autophagy. The common denominator of these three pathways 
is that the proteins are degraded in the lysosome, an acidic double-membrane vesicle containing 
proteolytic hydrolases. 
Macro-autophagy (hereafter referred to as autophagy) is a multistep cascade which is 
initiated by the ULK complex [53]. The cytosolic proteins to be degraded are recognized by 
p62 [54], which then interacts with the LC3 interaction region of the LC3 proteins [55]. 
Conjugation of LC3 protein with either one or two phosphatidyl-ethanolamine moieties (LC3-
I and LC3-II respectively) regulate the elongation of autophagosome [56]. The autophagosome 
is then transported along the microtubule network to the lysosome, and fusion between the 
autophagosome and the lysosome gives access to lysosomal hydrolases for the proteins to be 
degraded. Micro-autophagy differs in that it omits the cargo delivery, and instead direct 
invaginations in the lysosome sequesters proteins to be broken down [57]. Chaperone mediated 
autophagy utilizes the heat shock cognate protein of 70kDa to deliver proteins to the lysosome 
[58]. 
Whether a protein is destined to be degraded by the autophagic cascade or the proteolytic 
cascade is partly defined by the post-translational modification with ubiquitin. Ubiquitin is as 
the name implies a phylogenetically conserved protein which has a wide range of functions 
including cell cycle progression, signaling and protein degradation. It is a small, 8 kDa, protein 
that is attached via the action of E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating 
enzyme and E3 ubiquitin-ligase enzymes (reviewed in [59]). Ubiquitin is conjugated to a target 
protein either as a monomer, or as a chain of varying length, where the molecular function of 
the chain is dependent on both the number of ubiquitin monomers, and the linkage of the 
ubiquitin monomers in the chain. Poly-ubiquitination with more than 4 Lys48 linked ubiquitin 
monomers usually targets proteins to the proteasomal system [60]. Poly-ubiquitination  linked 
by Lys63 destines a protein to be degraded by both the autophagic machinery [61-63] and the 
proteasomal degradation machinery [64], while Lys48 poly-ubiquitination  appears to be more 
specific to proteasomal degradation than Lys63 poly-ubiquitination  [65]. 
Two specific E3 ligases stand out in the context of skeletal muscle atrophy: Muscle Ring 
finger 1 (MuRF1) and Muscle F box (MAFbx also known as atrogin-1). These proteins are 
essential for skeletal muscle atrophy as illustrated by the fact that MuRF1 and MAFbx deficient 
mice have attenuated muscle atrophy after denervation [66]. MuRF1 deficient mice are 
resistant to dexamethasone treatment, while MAFbx are not, indicating that different atrophic 
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stimuli are regulated through different transcriptions factors [67]. They are also widely 
implicated in human conditions, where spinal cord injury is known to regulate their protein 
content [68] and gene expression [69]. 
Skeletal muscle degradation is coordinated by both long acting transcriptional regulation, 
and acutely by signaling cascades. The Akt signaling axis is (once again) at the nexus of 
catabolic regulation. Akt activation leads to the activation of mTORC1 signaling cascade as 
outlined above, phosphorylation and inhibition of Ulk1, and thus attenuated formation of 
autophagosomes [53]. Conversely, AMPK promotes autophagy by phosphorylating Ulk1 on a 
separate, stimulatory residue [53, 70]. Furthermore, Akt regulates transcription of proteasomal 
and autophagosomal effectors, by phosphorylating the forkhead box (FOXO) family of 
proteins [71] (Fig. 2). Phosphorylation of FOXO transcription factors leads to association with 
14-3-3 binding proteins, and nuclear exclusion (as elaborated in section 1.5.1). Thus Akt 
stimulation inhibits autophagy through mTORC1 activation, and by inhibiting transcription of 
target proteins. Intriguingly, insulin resistance per se induces muscle atrophy in rodent models 
through increased proteolysis, indicating again the close coordination of energy and mass 
homeostasis [72].  
Skeletal muscle mass plasticity is achieved by modifying the rates of protein synthesis and 
degradation. Spinal cord injury is a clear example of this, where skeletal muscle mass is greatly 
reduced during the first year (elaborated in section 1.6). Understanding the signals and 
mechanisms underlying this fairly severe condition, will shed light on how aging and sedentary 
behavior affects skeletal muscle mass and in extension health. 
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1.4  AMPK 
1.4.1 AMPK structure and regulation 
AMPK senses the cellular energy status and orchestrates the molecular adaptations to low 
energy through modulation of both signaling pathways and gene transcription. AMPK is a 
heterotrimeric protein comprising of the catalytic α subunit, and regulatory β and γ-subunits. 
The α- and β-subunits are encoded by two genes, while the γ subunit is encoded by three genes, 
yielding 12 potential AMPK complexes. AMPK activity is dependent on both phosphorylation 
and increased cytosolic AMP concentration [73]. The α-subunit contains the kinase domain 
mediating AMPK phosphorylation of target proteins [74]. The γ-subunit is the site of AMP 
detection, through 4 tandem cystathionine-β-synthase motifs, which bind and detect AMP [75]. 
The cystathionine-β-synthase motifs can bind both ADP and AMP, with the latter being more 
probable for AMPK activity in vivo [76]. Finally the β-subunit contains a carbohydrate binding 
motif that allows AMPK to interact with glycogen [77]. 
The mechanism and sequence of events through which AMP regulates AMPK is not 
completely elucidated but involves several mechanisms. Potential mechanisms of how AMP 
regulates AMPK include alteration of Thr172 de-phosphorylation by inhibition of AMPK 
phosphatases [78], allosteric regulation of AMPK [79], and AMPK phosphorylation by 
upstream kinases [23]. Phosphorylation of the α subunit at Thr172 is necessary for AMPK 
activation, and is mediated by liver kinase B (LKB1) [80] and Ca2+/Calmodulin-dependent 
protein kinase kinase β (CaMKKβ) [81]. While LKB1 appears to be constitutively active [82], 
CaMKKβ activity is dependent on intracellular Ca2+, thus integrating outside signals to AMPK 
activity. While phosphorylation is important, the allosteric regulation of AMPK by AMP is 
probably the major point of AMPK activity regulation in vivo [76].  
1.4.2 AMPK and skeletal muscle mass homeostasis 
As AMPK integrates information on cellular energy status, it is a critical component in 
regulating skeletal muscle mass and energy metabolism. The role of AMPK in the regulation 
of skeletal muscle is dual, increasing degradation and decreasing synthesis. As outlined above, 
AMPK mediated phosphorylation and inhibition of raptor leads to decreased protein synthesis 
through reduced mTORC1 activity. Indeed, AMPK deficient rodents have increased skeletal 
muscle fiber diameter and increased p70S6K phosphorylation [83], AMPK activation is 
concomitant with reduced 4E-BP1 phosphorylation and reduced protein synthesis during 
exercise [84], and AMPK activation attenuates electrical stimulation induced increase in 4E-
BP1 and p70S6K phosphorylation [85]. These data suggest that AMPK activation, indicating 
energy deficiency, is inhibitory to protein synthesis. Conversely, AMPK activation leads to 
increased FOXO3 transcriptional activity, and autophagy as elaborated in section 1.5.1. 
Figure 2. Continued from previous page. Dashed line indicates several steps not shown here, arrow indicates stimulation of 
activity, and oval arrow are indicates inhibition of activity. PDB files to generate figures: 1fnt, 3l5q, 1e7i and 1aoi. 
Chromosome image is from Wikipedia (license not necessary, public domain).  
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1.4.3 AMPK and energy homeostasis 
AMPK activation leads to phosphorylation of substrates on motif (L/M)XRXX(S/T)XXXL 
[39], where X denotes any residue, and one letter amino acid abbreviations are shown. One of 
the most important enzymes phosphorylated by AMPK is Acetyl-CoA carboxylase (ACC), 
which is also the most common proxy for quantifying in vivo or in vitro AMPK activity. ACC 
generates malonyl CoA which in turn inhibits carnitine palmitoyl transferase 1 (CPT1) [86]. 
Phosphorylation of ACC by AMPK decreases the intracellular malonyl CoA concentration, 
lifting CPT1 inhibition and increasing influx of fatty acids into the mitochondria for β-
oxidation [87]. 
AMPK also regulates glucose transport, storage and oxidation. Interestingly, AMPK has an 
insulin independent effect on GLUT4 translocation [22] (which in turn is the major glucose 
transporter in skeletal muscle), linking energy status to energy availability independently of 
hormonal signaling. AMPK stimulates GLUT4 translocation by phosphorylating and inhibiting 
TBC1D4, which in turn inhibits GLUT4 translocation [88]. Since AMPK is responsible for 
detecting cellular energy state, and is involved in the skeletal muscle mass regulation, 
understanding AMPK signaling modulation in atrophic conditions is key for elucidating how 
skeletal muscle mass is related to energy metabolism. 
1.5 FOXO 
In general terms, FOXO proteins are potent gene transcription regulators, which control cell 
cycle progression, DNA repair, antioxidant enzyme expression, autophagy and apoptosis. 
FOXO proteins are under the regulation of IGF1/IRS1/Akt signaling axis, which has been 
implicated in murine longevity models. Furthermore, both the Ames and Snell dwarf strains 
(with impaired growth hormone - IGF1 signaling) [89], as well as heterozygotic IGF1 
knockouts [90], have increased life-span. 
Genetic variants of FOXO1, FOXO3 and Akt 
are linked to increased human life span in 
genome wide association studies (reviewed in 
[91]). This proposes a relationship between 
energy metabolism and longevity, and might 
implicate Akt signaling cascade and FOXO 
signaling in metabolic health. 
1.5.1 FOXO protein structure and 
regulation 
The mammalian FOXO protein family 
consists of 4 paralogs: FOXO1 (also denoted 
FKHR), FOXO3 (also denoted FOXO3a or 
FKHRL1), FOXO4 (also denoted AFX) and 
FOXO6. FOXO2 was initially thought to be an 
additional paralog, but is considered today 
homologous to FOXO3, while FOXO5 is only 
expressed in zebrafish [92]. FOXO proteins 
share an approximately 100 residue, helix turn 
helix, forkhead box motif mediating DNA 
interaction (Fig. 3). With the exception of this 
forkhead box motif, the FOXO proteins are 
disordered, and the disordered region regulates 
Figure 3. Crystal structure of binding domain of FOXO1 
protein bound to DNA helix. PDB id 3CO7. 
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subcellular localization, and transcriptional activity by recruitment of additional regulatory 
proteins, and has several regulatory post translational modification sites for phosphorylation, 
acetylation and ubiquitination. 
Akt mediated phosphorylation of FOXO proteins on three conserved sites leads to FOXO 
sequestration to the cytoplasm through interactions with the chaperone protein 14-3-3 [93, 94]. 
FOXO3 protein is also phosphorylated and activated by AMPK [95], while FOXO1 
phosphorylation by AMPK leads to increased degradation through a different mechanism than 
FOXO3 [96].  Conversely, dephosphorylation of FOXO proteins by protein phosphatase 2A 
leads to FOXO activation [94, 97]. 
FOXO proteins regulate gene transcription by several mechanisms. The transactivation 
domain of FOXO1 interacts directly with PGC-1α to regulate gene transcription [98], and 
FOXO3 proteins form complexes with histone deacetylase 2 [99] repressing gene transcription, 
and interacts with CBP/p300 histone acetyltransferases [100] stimulating gene transcription. 
1.5.2 FOXO and energy homeostasis 
FOXO1 and FOXO3 are intimately involved in the regulation of energy metabolism. In 
liver, FOXO1 and FOXO3 regulate mitochondrial energy utilization, glycolysis and 
lipogenesis [101, 102]. In muscle, FOXO1 drives the expression of PDK4 [103], leading to 
inhibition of glucose oxidation, and also regulates the expression of lipoprotein lipase [104] 
and the fatty acid transporter CD36 [105] increasing the lipid oxidation. This is further 
supported by the observation that muscle from insulin resistant humans shows decreased 
expression of FOXO-target genes [106], while also showing impaired fatty acid oxidation. 
Thus FOXO proteins are involved in the regulation both glucose and lipid metabolism. 
1.5.3 FOXO and skeletal muscle mass 
FOXO proteins are involved in skeletal muscle atrophy [71]. Simultaneous ablation of 
FOXO1, FOXO3 and FOXO4 in mice reduces skeletal muscle loss after denervation, 
attenuated expression of autophagic and proteasomal gene expression, as well as attenuated 
increase of Lys48 and Lys63 poly-ubiquitinated proteins after fasting [107]. At the same time, 
the increased autophagic and proteasomal loss of skeletal muscle mass induced by the 
simultaneous deletion of insulin and IGF-1 receptor, is attenuated by the concomitant deletion 
of FOXO1-4 [108]. This highlights the important role of the Akt signaling cascade, and FOXO 
proteins in catabolism. Consistent with these observations, atrophic stimuli in human skeletal 
muscle induces increased FOXO1 protein content and expression [109]. 
1.5.4 FOXO and inflammation 
The role of FOXO proteins in inflammatory signaling is not well understood, but is thought 
to involve both pro-inflammatory, and anti-inflammatory functions. FOXO1 regulates T cell 
infiltration by regulating expression of among other the chemokine receptor CCR7 in both T 
cells [110] and B cells [111]. In vivo, both FOXO1[110] and FOXO3 [112] deficiency leads to 
increased inflammation, and T cell activation. Whether this translates to regulation of muscle 
inflammation is currently unknown. Interestingly, corticosteroids induce loss of skeletal 
muscle mass, decreased inflammation, and increased FOXO expression [113], suggesting that 
FOXO proteins could be involved in integrating these mechanisms. 
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1.6 SPINAL CORD INJURY 
The incidence of spinal cord injury in Sweden is between 12 and 18 cases per million and 
year [114]. Spinal cord injury causes partial or total interruption of neural signaling below the 
level of injury depending on whether the spinal cord is completely or partially damaged. The 
height at which the spinal cord is injured impacts whether only the legs (paraplegia) or both 
arms and legs are affected (tetraplegia). The lack of neural input, and subsequent skeletal 
muscle inactivity leads to dramatic changes in body composition, skeletal muscle fiber type, 
and metabolic health.  
Immediately after spinal cord injury, skeletal muscle below the injury site undergoes major and 
rapid changes. Skeletal muscle cross sectional area is reported to decrease between 50% and 
80% in the first year after spinal cord injury [115, 116]. The loss in skeletal muscle cross 
sectional area is accompanied by an increase in intramuscular fat [117, 118], further impairing 
both recovery potential, and whole-body metabolic health. Additionally, the fiber type 
composition of skeletal muscle switches from its normally mixed composition, to a 
predominantly glycolytic composition, with the majority of the fibers becoming type IIx [68, 
119, 120]. The mechanism communicating and mediating the loss of skeletal muscle mass, and 
the changed fiber type composition is not completely understood, but involves to some extent 
insulin signaling, calpains, and autophagic degradation [121], with the majority of proteolysis 
being mediated by proteasomal degradation [122]. 
Spinal cord injury induces profound loss of muscle mass, which when combined with the role 
of skeletal muscle in glucose metabolism, leads to reduced peripheral glucose disposal during 
an euglycemic hyperinsulinemic clamp [13] and oral glucose challenge [118]. Isolated skeletal 
muscle from spinal cord injured subjects has similar levels of GLUT4 in crude membrane 
extracts as un-injured controls, in addition to unchanged ex vivo glucose uptake upon insulin 
stimulation [13], which combined with the observed fiber type switch is even harder to 
reconcile. At the same time, spinal cord injury induces changes in FOXO signaling [68] and 
energy metabolism enzymes [109], indicating that the observed whole-body metabolic 
derangements are a combination of decreased muscle mass, and changed energy handling. 
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2 AIMS 
Skeletal muscle plays a role in metabolic health by influencing several interconnected 
mechanisms. As skeletal muscle (and really all) metabolic processes are imperfect, some of the 
potential energy can “leak” from the tightly regulated biological cascades becoming mainly 
reactive oxygen species. Effective handling of these reactive oxygen species is essential for proper 
skeletal muscle function, and in extension whole-body health. Furthermore, skeletal muscle is 
remarkably plastic in terms of both muscle mass, and energy metabolism according to energy 
availability and needs. This adaptation is mediated by AMPK, which functions as detector of the 
ADP to ATP ratio, and phosphorylates various targets regulating energy production and 
consumption, as well as other essential singling cascades in the organism. Another essential aspect 
of skeletal muscle health is the coordination of appropriate gene transcription depending on 
energy, and overall anabolic or catabolic status. FOXO is responsible for integrating the energy 
status and homeostatic needs through control of gene transcription. Finally, signals from FOXO, 
AMKP, and various other sources integrate to regulate total skeletal muscle mass. The 
mechanisms mediating skeletal muscle mass adaptations to changed homeostatic needs are 
incompletely understood. Understanding how skeletal muscle degradation is regulated will enable 
therapies for ameliorating the negative consequences of aging, diabetes and spinal cord injury.  
In this thesis, I present four interrelated articles that center on understanding the above 
processes and aim to dissect the regulation of skeletal muscle plasticity and energy metabolism. 
Specifically, the following aims will be addressed:  
1. The role of ROS on insulin action and protein signaling, 
2. The role of AMPK in skeletal muscle fiber type after spinal cord injury, 
3. The mechanisms regulating skeletal muscle mass after spinal cord injury, 
4. The role of FOXO proteins in energy metabolism. 
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3 EXPERIMENTAL PROCEDURES 
3.1 HUMANS STUDIES 
3.1.1 General clinical characteristics 
Please see table 1 for volunteers participating in Study I, table 2 for spinal cord subjects 
participating in an 8 week training program in study II, and table 3 for spinal cord injured 
subjects and able-bodied controls for studies II and III. All studies were approved by the 
respective regional ethics committees of Victoria University, Helse Sør-Øst Trust, and 
Karolinska Institutet. The study protocol adhered to the principles expressed in the 
Declaration of Helsinki, and all subjects provided written, informed consent. 
Table 1. Volunteer characteristics in study I. 
Age (yr) 22.1 (3.2) 
BMI (kg/m2) 24.8 (3.0) 
Height (m) 1.8 (0.1) 
Weight (kg) 81.1 (14.1) 
Gender (male/female) 7/1 
VO2 peak (ml/kg/min) 50.6 (4) 
Data are mean and SD. 
 
Table 2. Spinal cord injured subject characteristics undergoing 8 week exercise training in study 
II. 
Subject Age (yr) Height (m) Weight (kg) BMI Time since injury Injury level 
A 44 1.87 87.5 25 23 C7 
B 32 1.86 69 19.9 11 C6 
C 38 1.85 80 23.4 7 C5 
D 28 1.86 64 18.5 6 C 
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3.2 NAC STUDY 
3.2.1 Cycle ergometer 
Participants performed a 55 minute bout of cycling exercise at a workload corresponding 
to 65% of their V̇O2peak. Following this, the workload was increased to that which 
corresponded to 85% of their VO2peak for the final five minutes to maximize the physiological 
demands of the exercise session. 
3.2.2 Euglycemic hyperinsulenimic clamp 
Insulin sensitivity was determined using a hyperinsulinemic-euglycemic. Briefly, 3 hrs 
after the exercise bout, insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) was infused 
(initial bolus 9 mU.kg-1 then continuously at 40 mU/m2.min) for approximately 120 min, with 
plasma glucose maintained at approximately 5 mmol.L-1, using variable infusion rates of 25% 
v/v glucose. Blood glucose concentration was assessed every 5 min using a glucose analyzer 
(YSI 2300 STAT Plus™ Glucose & Lactate Analyser, Australia). Glucose infusion rates 
(GIRs) were calculated during steady state, defined as the last 30 min of the insulin-
stimulated period and expressed as glucose (milligrams) per body surface area (square meter) 
per minute. Insulin sensitivity was expressed via the M value, where mean glucose infusion 
rate (I, in mg/kg/min) over the final 30 min of the insulin clamp is divided by the mean insulin 
concentration in mU/L (M/I: glucose infusion rate/insulin concentration). 
3.2.3 NAC infusion 
N-acetylcysteine (NAC; Parvolex, Faulding Pharmaceuticals, Melbourne, Australia) was 
infused intravenously with an initial loading dose of 62.5 mg.kg-1.hr-1 for the first 15 min, 
followed by a constant infusion of 25 mg.kg-1.h-1 for the next 80 minutes using a syringe 
pump (Graseby 3400, Graseby Medical, UK). Plasma NAC concentration was later analyzed 
by reversed-phase ultra high performance liquid chromatography. 
3.3 SPINAL CORD INJURY STUDY 
3.3.1 Spinal cord injury subjects 
The spinal cord injured individuals received standard upper body physical therapy, and 
postural stability exercises during the time studied. 
3.3.2 Spinal cord injury electrically stimulated ergometry 
The training period consisted of seven exercise sessions per week, with one session per 
day for 3 days and two sessions per day for 2 days. The training bouts were carried out on a 
computer-controlled electrical stimulation exercise ergometer (ERGYS-I-Clinical 
Rehabilitation System; Therapeutic Alliances, Fairborn, OH). All electrically stimulated leg 
cycling sessions were supervised by a physician and a physiotherapist. No electrically 
stimulated leg cycling bouts were performed during the 48 h before muscle biopsies were 
obtained. 
3.4 MUSCLE BIOPSY PROCEDURES 
The volunteers participating in study I were provided with a food parcel the day before 
the experiment (14 MJ, 80% carbohydrate) and instructed to abstain from alcohol, exercise 
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and caffeine to standardize pre-experimental muscle glycogen content. Any diet 
inconsistencies occurring prior to the first trial were replicated for the second trial. Muscle 
samples were obtained from the middle third of the vastus lateralis muscle using the 
percutaneous needle biopsy technique. After injection of a local anesthetic into the skin and 
fascia (1% Xylocaine, Astra Zeneca, Australia), a small incision was made and a muscle 
sample taken (approximately 100-200 mg) using a Bergström biopsy needle with suction. 
Each biopsy was taken from a separate incision, 1-2 cm distal from the previous biopsy. 
Muscle samples were washed free of blood and dissected of any other tissue then immediately 
frozen in liquid nitrogen. The volunteers of study II, and study III used a similar biopsy 
technique while in a postprandial state. 
3.5 ANIMAL STUDIES 
3.5.1 Animal housing conditions 
Animal experiments were approved by the Regional Animal Ethical Committee 
(Stockholm, Sweden). Male C57BL/6J mice (30 week old) were purchased from Janvier 
(France). Mice received ad libitum access to water and standard rodent chow (Lantmännen, 
Sweden), and were housed on a 12 h light/dark cycle. 
3.5.2 Plasmid design 
FOXO1dn negative sequence was the same as previously described [123] consisting of 
amino acids 1-256. FOXO3dn was designed by aligning murine amino acid sequence to 
previously described dominant negative human sequence [124] yielding a 1-249 amino acid 
sequence. The FOXO1dn and FOXO3dn amino acid sequences obtained were optimized and 
converted to nucleotide sequences by GeneArt, and plasmids including empty control vector 
were synthesized by GeneArt (Invitrogen GeneArt, ThermoFisher Scientific, Rockford, IL). 
3.5.3 Plasmid electroporation 
Following one week of acclimatization, tibialis anterior muscle was transfected with 
either a control plasmid or plasmid encoding for FOXO1dn or FOXO3dn (Invitrogen 
GeneArt, ThermoFisher Scientific, Rockford, IL). Mice were anesthetized with isoflurane 
before hyaluronidase (30 μl of 1 unit/μl) transdermal injection of the tibialis anterior muscle. 
Mice were allowed to rest in individual cages for 2 h, after which they were again 
anesthetized with isoflurane. Plasmids (30 μg) were injected in the tibialis anterior muscle 
of each leg transdermally, and constructs were electroporated with 220 V/cm in 8 pulses of 
20 milliseconds using an ECM 830 electroporator (BTX Harvard Apparatus, Holliston, MA). 
3.5.4 Modified oral glucose tolerance test 
One week post-electroporation, mice were fasted for 4 h, and glucose uptake was 
measured in vivo using a modified oral glucose tolerance test.  A bolus of glucose (3 gm/kg) 
was administered through oral gavage, and [3H] 2 deoxy-glucose (4.5 μl of 2-[3H]deoxy-D-
glucose/100 μl of saline/animal, 1 mCi/ml) was injected intraperitoneally. Mice were 
terminally anesthetized using avertin 120 min after the glucose gavage, and the tibialis 
anterior muscle was dissected, washed clean in phosphate buffered saline, and rapidly frozen 
in liquid nitrogen for subsequent determination of [3H]glucose uptake. Frozen muscle 
samples were homogenized in ice-cold buffer (10% glycerol, 5 mM sodium pyrosulfate, 13.7 
mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 20 mM Tris (pH 7.8), 1% Triton X-100, 10 mM NaF, 
1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 
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0.5 mM sodium vanadate, 1 mM benzamidine, and 1 μM microcystin) with dry ice cooled 
mortar and pestle. Homogenates were rotated end-over-end for 1 h at 4 °C and then subjected 
to centrifugation at 12,000 × g for 10 min at 4 °C. The supernatant (30 μl) was analyzed by 
liquid scintillation counting. A portion of the remaining supernatant was stored at −80 °C for 
immunoblot analysis. 
3.5.5 Cell culture growth 
C2C12 myoblasts were purchased from Sigma Aldrich and propagated in high glucose 
DMEM supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. They 
were passaged every 2 days. 
3.5.6 Cell culture transfection 
Cells were seeded in a 6 well plate at 20 000 cells/well, and transfected with FOXO1dn, 
FOXO3dn, or control, using Lipofectamine 3000 according to manufacturer instructions. 
Experiments were performed 48 h after transfection. 
3.6 ANALYTICAL METHODS 
3.6.1 Immunoblot analysis 
Portions (30 – 60 mg) of the muscle samples were freeze-dried and dissected free of visible 
fat, blood, and connective tissue at room temperature. The specimens were homogenized in 
0.6 ml of ice cold lysis buffer (137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl, 1 mM EDTA, 20 
mM Tris, pH 7.8, 5 mM Na pyrophosphate, 10 mM NaF, 1% Triton X-100, 10% (vol/vol) 
glycerol, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM Na3VO4 and 1X protease 
inhibitor cocktail Set 1 (Calbiochem, EMD Biosciences, San Diego, CA)) or protease 
inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Insoluble material was 
removed by centrifugation at 12,000 g for 10 min at 4°C, and supernatant protein 
concentration was determined using a commercially available assay (Pierce BCA protein 
assay kit; Thermo Scientific, Rockford, IL). Equal amounts of protein were diluted in 
Laemmli buffer, separated by SDS-PAGE electrophoresis (Criterion XT Precast gel; Bio-
Rad, Hercules, CA), and were transferred to PVDF membranes. Equal loading was confirmed 
by Ponceau S staining. The membranes were blocked with 5% nonfat dry milk in TBST (20 
mM Tris, 137 mM NaCl, 0.02% Tween 20, pH 7.6) for 1 h at room temperature and incubated 
overnight at 4°C with appropriate primary antibodies diluted 1:1000 in TBS with 0.1% BSA 
and 15 mM NaN3. Membranes were washed in TBST and incubated with the respective 
secondary antibodies diluted in 5% nonfat dry milk in TBST, as recommended by the supplier 
(Amersham, Arlington, IL). Proteins were visualized by enhanced chemiluminescence 
(Amersham) and quantified by densitometry using Quantitity One software (Bio-Rad). 
3.6.2 Protein carbonylation 
Protein carbonylation analysis was performed on snap frozen muscle samples using the 
OxyBlot Protein Oxidation Detection kit (Millipore, Billerica MA) as per manufacturer 
instructions, except lysis was performed without the addition of β-mercaptoethanol. Protein 
carbonylation was then determined via electrophoresis and immunoblotting as per Western 
blot analysis. 
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3.6.3 Antibodies used: 
 
Target 
Catalogue 
number 
Company 
4E-BP1 9644 Cell signaling 
4E-BP1 9452 Cell signaling 
Akt 9272 Cell signaling 
AMPKα1 07−350 Millipore 
AMPKα2 07−363 Millipore 
AMPKβ1 1604−1 Epitomics 
AMPKβ2 H-75 sc20146 Santa Cruz 
AMPKγ1 1592−1 Epitomics 
AMPKγ3 HPA004909 Sigma-Aldrich 
FOXO1 12161 Abcam 
FOXO3 ab47409 Abcam 
GLUT4 07-1404 Millipore 
GS 3839 Cell signaling 
GSK3b 9315 Cell signaling 
Hexokinase 2 not applicable kind gift from Oluf Pedersen 
LC3A/B L8918 Sigma-Aldrich 
 28 
MAFbx sc-166806 Santa Cruz 
MHC I, IIa, and IIx not applicable 
kind gift from Stefano 
Schiaffino 
MitoProfile Total OXPHOS 
Human 
ab110411 Abcam 
mTOR 2983 Cell signaling 
MuRF1 sc-32920 Santa Cruz 
MitoProfile total OXPHOS 
Rodent 
ab110413 Abcam 
p-4EBP1 Thr37/46 2855 Cell signaling 
p62 P0067 Sigma-Aldrich 
p70S6K 9205 Cell signaling 
p-ACC Ser79 3661 Cell Signaling 
p-Akt Ser473 9271 Cell signaling 
p-Akt Thr308 4056 Cell signaling 
p-AMPKα Thr172 2531 Cell Signaling 
p-FOXO1 Ser256 9461 Cell signaling 
p-FoxO3 Ser253 13129 Cell signaling 
p-GS Ser641 3891 Cell signaling 
p-GSK3b Ser9 9323 Cell signaling 
p-mTOR Ser2448 5536 Cell signaling 
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p-mTOR Ser2448 600-401-422 Rockland 
p-p70S6K Thr389, 
Thr421/Ser424 
2708 Cell signaling 
Proteasome 20S α ab22674 Abcam 
p-S6 Ser235/236 2211 Cell signaling 
p-STAT1 Tyr701 9171 Cell signaling 
raptor 2280 Cell signaling 
S6 2317 Cell signaling 
STAT1 9172 Cell signaling 
TSC2 4308 Cell signaling 
Ubiquitin linkage-specific Lys48 ab140601 Abcam 
Ubiquitin linkage-specific Lys63 ab179434 Abcam 
Appropriate anti-rabbit, and anti-mouse antibodies were purchased from BioRad. 
3.6.4 Skeletal muscle glycogen determination 
Glycogen content assay was performed on freeze dried or thawed muscle samples (from 
previous storage in -80oC), using a commercially available kit following manufacturer 
instructions (Abcam). Glycogen content was normalized to dry muscle sample weight. 
3.6.5 Glucose uptake in C2C12 
Cells were serum starved for 4h in 1 g/L DMEM, and subsequently incubated in the 
absence or presence of 120 nM insulin (Actrapid Novo Nordisk, Denmark) for 30 minutes. 
Thereafter, myoblasts were incubated in glucose-free medium containing 2-[1,2-3H]deoxy-
D-glucose (1 mCi/ml; Moravek) 15 min in the absence or presence of insulin. Cells were 
lyzed in 0.03% SDS and analyzed for [3H] content using liquid scintillation counting 
(WinSpectral 1414, Wallac). Each experiment was performed in duplicate, and the data is 
the average of five experiments. 
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3.6.6 GSH:GSSG measurement 
Total (tGSH) and oxidized (GSSG) muscle glutathione content was determined 
spectrophotometrically using a commercially available kit (Bioxytech GSH/GSSG-412, Oxis 
Health Products, Portland, OR, USA) according to manufacturer instructions. Freeze dried 
muscle was dissected free of connective tissue, divided into two aliquots then powdered and 
weighed. Muscle was then homogensized with 80 μL.mg-1 (dry weight) ice-cold 5% 
metaphosphoric acid with and without 1-methyl-2-vinyl-pyridinium trifluoromethane 
sulphonate (M2VP; 10% v/v). Homogenate was centrifuged at 23 000 g for 15 min at 4 ºC. 
The resulting supernatant was diluted 1:25 (tGSH), and 1:20 (GSSG) in assay buffer. 
Samples, standards and blanks (50 μL) were added to a 96 well plate in triplicate, followed 
by 50 μL of chromagen, 50 μL glutathione reductase and just prior to measurement, 50 μL 
NADPH. Change in absorbance (reduction of dithiobis-2-nitrobenzoic acid) was measured 
at 412 nm at 30 sec intervals for 4.5 min in a spectrophotometer (xMark; Bio-Rad 
Laboratories, Inc., Hercules, California, USA). Pellets remaining from the centrifuged 
homogenate were dissolved in 1 N NaOH, heated at 60 ºC with agitation then assayed for 
protein content (Bio-Rad). Glutathione values reported are normalized to protein content. 
3.6.7 Insulin determination 
Plasma insulin concentration was determined using a 96 well ELISA insulin kit (Dako, 
Denmark) according to the manufacturer’s protocol. Briefly, duplicates of 25 µL plasma 
samples and standards were combined with a conjugate diluent. A conjugate concentrate 
mixture was then added to each well and the plate was shaken for 1 hour. Well contents were 
removed then washed three times using supplied wash buffer. After washing, substrate 
solution was added and placed in a shaker for 10 min. A stopping solution was then added 
before determining absorbance at 460 nm using a micro plate reader (iMark Microplate 
Absorbance Reader, Bio-Rad, Denmark). 
3.7 GENE EXPRESSION ANALYSIS 
3.7.1 qPCR 
qPCR analysis was performed on total RNA from electroporated tibialis anterior muscle. 
RNA was extracted with Trizol following manufacturer’s recommendations (Life 
Technologies). Total RNA concentration was quantified spectrophotometrically (NanoDrop 
ND-1000 Spectrophotometer, ThermoFisher Scientific). RNA was reverse-transcribed to 
cDNA using the High Capacity cDNA RT kit and gene expression was determined by real-
time PCR using SYBR Green reagent (Life Technologies, ThermoFisher Scientific). 
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Table 5. Primer sequences  
 
Gene Forward Primer Reverse primer 
Foxo1 CTGCAGATCCCGTAAGACG GGTCACCGGTGTCTAAGGAG 
Foxo3 GGAAGGGAGGAGGAGGAATG CTCGGCTCCTTCCCTTCAG 
Ccl2 AGCCAACTCTCACTGAAGCC TTCTTGGGGTCAGCACAGAC 
Ccl7 CCACCATGAGGATCTCTGCC ATAGCCTCCTCGACCCACTT 
Ccl8 TTTGCCTGCTGCTCATAGCT TGTGAAGGTTCAAGGCTGCA 
Cxcl9 ACCTCAAACAGTTTGCCCCA ACGACGACTTTGGGGTGTTT 
Cd68 AAGGTCCAGGGAGGTTGTGA ATGAATGTCCACTGTGCTGC 
Cd48 CTCGGGACCTTTCCCCAAAA ACTAGCCAAGTTGCAGTCCA 
Itgax CCAGCCAGAGGATTTCAGCAT CTGCAGGTGTGAAGTGAACAG 
Cd3g ACTGTAGCCCAGACAAATAAAGC TGCCCAGATTCCATGTGTTTT 
Ncr1 GAGCCAGAGGATCAACACTG ATGGCTTTGGTCTCTCCAAGG 
Ly6c ACCCTTCTCTGAGGATGGACA GCTGGGCAGGAAGTCTCAAT 
Tbp CCTTGTACCCTTCACCAATGAC ACAGCCAAGATTCACGGTAGA 
3.7.2 Transcriptomic analysis 
Microarray analysis was performed on total RNA extracted from electroporated TA 
muscle utilizing the EZ RNA extraction kit, and hybridized to an Affymetrix Mouse Gene 
2.1 ST array (ThermoFisher Scientific) at the core facility for Bioinformatics and Expression 
Analysis (BEA) at Karolinska Institutet. 
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3.8 STATISTICAL ANALYSIS 
3.8.1 Statistical analysis in study 1 
Data were analyzed by two-way (treatment x time) analysis of variance with repeated 
measures on both factors (IBM SPSS Statistics v20). Where significant main effects were 
detected, post hoc analyses were conducted with Student’s t-tests for pairwise comparisons 
and adjusted for multiple comparisons. Single comparisons (insulin sensitivity) were 
analyzed by using a paired Student’s t-test. Statistical significance was accepted at p<0.05. 
Raw data are presented as mean ± SD for n=7, and change scores are reported as fold-change 
of the mean, or percent difference where appropriate. 
3.8.2 Statistics used in study 2, and 3 
Data are reported as mean and individual values. The average phosphorylation, and 
lipidation ratio for each subject was calculated and the mean data for the entire study cohort 
is presented. Statistical significance was analyzed both with mixed-models analysis, and non-
parametric Friedmans test, followed by Dunns multiple comparison test for acute spinal cord 
injury, and non-parametric Mann–Whitney test for comparisons between spinal cord injured 
subjects studied 12 months after injury versus able-bodied control subjects. Correlation 
analysis was performed using spearman rank correlation, and heatmap was visualized in the 
R programing environment using the gplots package. Data in heatmap were normalized to 
have mean of 0 and standard deviation of ±1 per each measured protein. Statistical 
significance was accepted at p ≤ 0.05.  
3.8.3 Statistical analysis in study 4 
Data was analyzed in R utilizing the oligo package for the robust multi-array average 
normalization, and annotated using the transcriptcluster package. Transcriptome data was 
visualized using the factoextra and ggplots2 package. Gene set enrichment analysis was 
performed with the GSEA software (Broad Institute, MA) using the curated Molecular 
Signatures Database. All statistical tests are paired student t-test. A significance threshold 
was defined at p<0.05, except for the transcriptomic analysis, where significance was defined 
at p<0.01, with at least a 40% fold change in either direction. 
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4 RESULTS AND DISCUSSION 
4.1 EFFECTS OF ANTIOXIDANT INFUSION ON INSULIN SENSITIVITY AFTER 
EXERCISE. 
Antioxidant treatments attenuate the beneficial effects of exercise training [33]. We sought 
to study the effects of acute antioxidant treatment on exercise adaptations. This was performed 
by studying skeletal muscle metabolic adaptations, signaling cascades, and insulin sensitivity 
in 7 healthy male volunteers during: exercise, recovery and insulin infusion with the 
concomitant infusion of either N-acetyl-cysteine (NAC) or placebo (Fig. 4). 
Figure 4. Schematic representation of study design. The same protocol was used in two separate occasions with either 
NAC or control saline infusion >7 days apart. 
NAC infusion lead to a small (~6%) but significant 
decrease in insulin sensitivity (Fig. 5) as defined by the 
M-I index (glucose infusion rate of last 30 min divided 
by mean insulin concentration). 
Although the effect of NAC infusion on insulin 
sensitivity was modest, it is worth bearing in mind that 
the effect observed is an acute response. Furthermore, 4 
weeks of treatment with antioxidant vitamins show a 
similar effect size on insulin infusion rate as observed 
here [33]. This might indicate that effects of antioxidant 
treatment on insulin sensitivity are rapid, and non-
cumulative. 
The decreased glucose infusion rate was coincident 
with decreased markers of reactive oxygen species 
activity by two different measurements methods: protein 
carbonylation and GSH:GSSH ratio. Protein 
carbonylation showed a statistical main effect for NAC 
infusion, and only a trend (p=0.08) for decreased protein 
carbonylation after exercise (Fig. 6). The GSH:GSSG 
ratio on the other hand had a significant main effect, as 
Figure 5. Insulin sensitivity compared 
between control or NAC infused subjects. 
Bars represent means, ± SD for n=7 , 
arbitrary units (AU), with individual 
participant responses overlayed. * = p<0.05. 
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well as a trend for increased GSH:GSSG ratio immediately after exercise, and increased 
significantly after a 3 hour recovery period (Fig. 6). 
Figure 6. Effects of either NAC or saline control infusion on total protein carbonylation, and GSH:GSSG ratio. Data 
are means ± SD for n=7, arbitrary units (AU). * = p<0.05, p=0.08 denote trend for NAC vs. CON. 
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While the decreased protein 
carbonylation was not really 
striking, the decreased 
GSH:GSSG ratio was larger. 
Together these data indicate that 
NAC infusion leads to increased 
antioxidant potential of 
endogenous systems, which 
translates to a small decrease in 
oxidized proteins. 
Interestingly, the decreased 
insulin sensitivity was not 
accompanied by dramatic changes 
in signal transduction. Neither 
AMPK nor ACC phosphorylation 
was affected by NAC infusion 
(Fig. 7). This indicates that cellular 
energy availability was unaffected 
by NAC, and that AMPK is not 
affected directly by reactive 
oxygen species. Changes in the 
mTOR signaling cascade were 
contradictory. p-mTOR to total 
ratio, as well as p-4EBP-1 to total, 
and S6 phosphorylation were 
unaffected by NAC infusion. 
Conversely, p-p70S6K, the kinase 
responsible for S6 
phosphorylation, was decreased by 
NAC infusion (Fig. 7), indicating 
that there is a dissociation of 
normal p70S6K function with 
NAC infusion, or that the phosphorylation/dephosphorylation of p70S6K is affected by other 
upstream molecules that are themselves responsive to oxidative stress. One fascinating 
interpretation of the attenuated p70S6K, could be that antioxidant supplementation blunts 
protein translation, and that reduced protein translation is interfering with the positive effects 
of exercise. 
Additionally, one must consider the pharmacological effects of NAC in the context of 
insulin sensitivity and exercise. While NAC is considered to be a precursor for cysteine and 
GSG, it can also affect disulfide bridges through its thiol-disulfide exchange activity [125]. 
This leads to reduction and breakage of disulfide bonds, which in itself can have signaling 
activity. Whether the effects observed here are due to scavenging of reactive oxygen species, 
or by changes in the overall redox state is unknown and warrants further study. 
Figure 7. Effect of either NAC or saline control infusion on AMPK, and 
mTOR cascade protein signaling. Data are means ± SD for n=7, 
arbitrary units (AU). * = p<0.05 NAC vs. CON, † = p<0.05 vs BASE 
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4.2 EFFECTS OF SPINAL CORD INJURY ON SKELETAL MUSCLE 
COMPOSITION, METABOLISM AND SIGNALING. 
Spinal cord injury leads to increased intramuscular fat 
[117, 118]. This opens the possibility that any observed 
increases in protein content or phosphorylation are due to 
replacement of skeletal muscle by fat. We do not detect 
evidence of this, as the protein content of the lipid droplet 
coating protein perilipin 1, is not changed during the first year 
after spinal cord injury (Fig. 8). 
4.2.1 AMPK activation and subunit composition, 
oxidative phosphorylation enzymes, and MHC-
proteins after spinal cord injury. 
Spinal cord injury changes both composition, and energy 
metabolism of affected skeletal muscle. Thus we sought to 
quantify the AMPK subunit distribution, activity, and its 
correlation with mitochondrial complex protein content and 
fiber type distribution. These parameters were studied in 
able-bodied controls, individuals with complete longstanding 
spinal cord injury, and complete spinal cord injury during the 
first year after injury. 
AMPK phosphorylation on Thr172, and phosphorylation of ACC on Ser79, decreased by 
12 months after spinal cord injury, indicating that AMPK signaling activity is reduced during 
the first year after spinal cord injury (Fig. 9). This coincided with decreased protein content of 
AMPK subunit β1, and γ1, as well as increased protein content of AMPK subunit γ3 (Fig. 9). 
Conversely, incomplete spinal cord injury lead only to increased protein abundance of AMPK 
γ1 subunit (Fig. 7 in study II). Together these data indicate that skeletal muscle atrophy, instead 
of decreased neuronal signaling (due to incomplete spinal cord injury), induces a shift in energy 
metabolism as AMPK signaling is decreased, and changed AMPK subunit distribution. 
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Figure 8. Protein content of lipid droplet 
protein perilipin 1 during the first year after 
spinal cord injury. Representative Western 
blot is shown above with positive control 
(mouse adipose tissue) and 1, 3 and 12 
months after spinal cord injury. Red color 
indicates overexposure (signal saturation). 
Data are means ± sem, arbitrary units (AU), 
with individual participant responses 
overlayed. n=5. 
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Figure 9. AMPK signaling changes and AMPK β1, γ1, and γ3, subunit composition in skeletal muscle from 
subjects with spinal cord injury during the first year after injury. * p < 0.05. Representative Western blots are 
presented above each graph. Values are presented as means ± SE, arbitrary units (AU). n = 7. 
With long standing injury, we detected only decreased γ1 subunit and increased γ3 subunit 
protein abundance, indicating that the decrease in AMPK β1 subunit abundance observed 
during the first year is transient (Fig. 10). This might indicate that the β1 and α2 subunit are 
involved in regulating skeletal muscle mass and energy metabolism before skeletal muscle 
reaches steady state after chronic spinal cord injury. 
 
Figure 10. AMPK γ1 and γ3 subunit abundance in skeletal muscle from able-bodied individuals and subjects 
with long standing spinal cord injury. *p < 0.05. Representative Western blots are presented above each graph. 
Values are presented as means ± SE, arbitrary units (AU). n = 6–8. 
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The changes in AMPK signaling and isoform distribution are coincident with decreased 
abundance of mitochondrial complex proteins, and MHC-I protein, as well as increased MHC- 
IIa protein abundance after 12 months of complete spinal cord injury (Fig. 11). This suggests 
that changes in AMPK could be involved in the changes in MHC-distribution, and 
mitochondrial oxidative phosphorylation cascade. 
Figure 11. Protein content of mitochondrial complex proteins and MHC-protein content composition in skeletal 
muscle from subjects with spinal cord injury during the first year after injury. *P < 0.05. Representative Western 
blots are presented above each graph. Values are presented as means ± SE, arbitrary units (AU). n = 7. 
Conversely, long standing spinal cord injury leads to almost complete absence of MHC-I 
protein, and increased protein content MHC-IIa and MHC-IIx (Fig. 12). This provides evidence 
to suggest that the increased protein content of MHC-IIx occurs after 12 months.  
 
Figure 12. Protein abundance of MHC-isoforms in skeletal muscle from able-bodied individuals and subjects 
with long standing spinal cord injury. *p < 0.05. Representative Western blots are presented above each graph. 
Values are presented as means ± SE, arbitrary units (AU). n = 6–8. 
The change in AMPK signaling and subunit composition could be due to either adaptive 
changes to the energy homeostasis of skeletal muscle, or it could be a consequence of the 
skeletal muscle fiber type switch [126] due to spinal cord injury. As electrically stimulated 
skeletal muscle training of spinal cord injured individuals shows increased AMPK protein 
content [127], it is plausible that the lower energy flux due to inactivity is driving the decreased 
AMPK signaling detected here. Measuring AMPK activity in low energy flux conditions and 
intact neural signaling before fiber type switch (such as unloading induced by bed rest) will 
Able bodied SCI Able bodied SCI Able bodied SCI
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elucidate the whether changed AMPK signaling precedes the changes in skeletal muscle 
composition. 
4.2.2 Effectors and signaling molecules regulating skeletal muscle atrophy 
While it is known that spinal cord injury induces a large decrease in skeletal muscle mass, 
the mechanisms mediating the decrease in muscle mass are not completely understood. 
Decreased skeletal muscle mass can conceivably be a consequence of decreased protein 
synthesis, increased protein degradation, or both. Furthermore, the rate of decrease during the 
first year is not linear. The rate of loss is highest during the first 6 weeks, and continues at a 
slower rate thereafter [115]. To better understand how human skeletal muscle mass is regulated 
we quantified the signalling proteins regulating protein translation, proteasomal, and 
autophagic degradation at 1, 3 and 12 months after injury, as well as in able-bodied controls. 
mTOR protein content and phosphorylation, as well as protein content of raptor, the 
mTORC1 defining complex was decreased during the first year after spinal cord, indicating 
that anabolic signalling is decreased by spinal cord injury (Fig. 13). This was accompanied by 
decreased protein content of the ribosomal protein S6, an indirect indicator of protein 
translation (Fig.14). Together, the decreased phosphorylation and protein content of mTOR, 
and raptor, as well as the decreased S6 protein content and phosphorylation, indicate that at 
least one of the components underlying the physiological observation of decreased skeletal 
muscle mass after spinal cord injury is decreased protein translation. 
 
Figure 13. Changes in mTOR protein and phosphorylation, and mTORC1 complex protein raptor during the 
first year after spinal cord injury. Bars represent mean values, and individual data is plotted as gray line for n=7. 
Representative Western blots are presented above each graph. Values are arbitrary units (AU); *p<0.05 and **p<0.01. 
 
Figure 14. Protein content and phosphorylation of the ribosomal protein S6. Bars represent mean values, and 
individual data is plotted as gray line for n=7. Representative Western blots are presented above each graph. Values 
are arbitrary units (AU). **p<0.01. 
 40 
Before proteins are degraded, they need to be modified by ubiquitin ligases. We found that 
the transcription factor FOXO3, regulating transcription of both autophagic machinery and the 
ubiquitin ligases MuRF1 and MAFbx [71] decreased during the first year after injury (Fig. 15). 
This suggests that the degradation potential of skeletal muscle is at its highest at 1 month post 
injury, as the decreased protein content of the ubiquitin ligases decreases after that point. 
 
Figure 15. Protein content of FOXO3, and the skeletal muscle E3 ubiquitin ligases MuRF1 and MAFbx. Bars 
represent mean values, and individual data is plotted as gray line for n=7. Representative Western blots are presented 
above each graph. Values are arbitrary units (AU); *p<0.05 and **p<0.01. 
This is interesting to contrast with rodents undergoing corticoid induced muscle atrophy, as 
different atrophic stimuli induce skeletal muscle atrophy through different mechanisms. 
MuRF1 deficient animals are protected from corticoid induced muscle atrophy, and corticoids 
do not increase FOXO3 protein content [67], indicating that corticoid induced skeletal muscle 
atrophy is under FOXO1-MuRF1 control axis. We found that the protein content of MAFbx 
correlates positively with both FOXO1 and FOXO3 (Fig. 16), while MuRF1 does correlate 
with either. Although not causative, this observation implies that in spinal cord injury, as 
opposed to corticoid induced muscle atrophy, MAFbx is under direct control of FOXO1 and 
FOXO3 while MuRF1 is not.  
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MuRF1 and MAFbx are directly 
involved in ubiquitination of proteins in 
skeletal muscle. Surprisingly, the 
decreased protein content of MuRF1 and 
MAFbx did not lead to decreased Lys48, 
or Lys63 poly-ubiquitinated proteins 
during the first year after spinal cord 
injury (Fig. 17). Furthermore, the total 
amount of Lys48 poly-ubiquitination did 
not correlate with MuRF1 or MAFbx, and 
Lys63 poly-ubiquitination correlated 
negatively with MuRF1 (Fig. 18), further 
highlighting the disconnection between 
ubiquitination and MuRF1 and MAFbx in 
spinal cord injured skeletal muscle 
atrophy. 
Figure 17. Poly-ubiquitination of proteins with either Lys48, or 
Lys63 during the first year after spinal cord injury, and 
comparing 12 months after injury to able-bodied controls.  Bars 
represent mean values, and individual data is plotted as gray line 
for n=7 (n=6 for polyUb63 during first year). Representative 
Western blots are presented above each graph. Values are 
arbitrary units (AU); *p<0.05 and **p<0.01. 
Figure 16. Correlation analysis of MAFbx (open circles) and MuRF1 (closed circles) with total FOXO1 and 
FOXO3 protein content. Values are arbitrary units (AU); *p<0.05 and **p<0.01. n=7. 
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The observation that the decreased 
protein content of MuRF1, and MAFbx does 
not translate to attenuated ubiquitination of 
proteins can be explained by either decreased 
degradation of proteins, leading to their 
accumulation, or by other ubiquitin ligases 
acting in spinal cord injured muscle. 
Considering that ablation of MAFbx and 
MuRF1 does not lead to completely 
abolished denervation-induced skeletal 
muscle atrophy [66], both these possibilities 
are plausible. Moreover, there were more 
poly-ubiquitinated proteins with Lys48 at 12 
months when compared to able-bodied 
controls (Fig. 17). The most plausible 
explanation is that there is increased protein 
degradation, since it is quite implausible that 
proteasomal degradation is lower in spinal 
cord injured subjects compared to able-
bodied controls. The absent, or even negative 
correlation between MuRF1 and MAFbx and 
Lys48 and Lys63 poly-ubiquitin implicates 
again that either there is accumulation of 
Lys68 and Lys63 poly-ubiqutininated 
proteins due to decreased degradation, or that 
other other E3 ligases not measured play an 
additional role in ubiquitination after spinal 
cord injury. 
Breakdown of skeletal muscle proteins 
can be mediated by either autophagic or 
proteasomal degradation. We detected decreased abundance of the autophagosome initiating 
proteins, LC3-I and LC3-II, during the first year after spinal cord injury, but not when 
compared to able-bodied controls. Additionally, the structural α subunit of the proteasome 20S 
was unchanged during either the first year, or when comparing to able-bodied controls (Fig. 
19). This provides evidence to suggest that there is increased formation of autophagosomes 
during at 1 month, which returns to baseline by 12 months. The unchanged Lys48 poly-
Figure 19. Protein content of autophagy and proteasomal 
mediating degradation during the first year after spinal cord 
injury and when compared to able-bodied controls. Bars 
represent mean values, and individual data is plotted as gray line 
for n=7. Representative Western blots are presented above each 
graph. Values are arbitrary units (AU); *p<0.05 and **p<0.01. 
Figure 18. Correlation analysis of MAFbx (open circles) and MuRF1 (closed circles) with total poly-ubiquitination linked 
at Lys48 or Lys63 protein content. Values are arbitrary units (AU); *p<0.05 and n=7 for PolyUb48 and n=6 for PolyUb63. 
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ubiquitination during the first year after spinal cord injury, together with the increased Lys48 
poly-ubiquitination when comparing 12 months of spinal cord injury to able-bodied control, 
suggests that proteasomal degradation is increased during the first year, and remains higher 
than able-bodied controls. 
As both mTOR and AMPK stimulate autophagy, the decreased mTOR protein content in 
figure 13, and decreased AMPK signaling observed in figure 9 further support the notion that 
autophagy is higher at 1 month after spinal cord injury. It is also possible that the transiently 
increased autophagosomal degradation proposed here, is mediating the decreased 
mitochondrial complex proteins, and the decrease in MHC-I and IIa proteins observed in figure 
11. 
Figure 20 shows changes during the first 
year of spinal of all proteins measured. 
Changes are normalized by scaling (mean=0, 
and standard deviation ± 1). One striking 
observation is that the protein content of most 
measured molecules is decreased at 3 and 12 
months. This could indicate that skeletal 
muscle metabolic signaling is decreased, and 
that there is an increase in other proteins not 
measured here. Together, these data highlight 
the mechanisms underlying muscle plasticity 
in terms of adaptations to extreme inactivity. 
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Figure 20. Heatmap of all measured proteins during the 
first year after spinal cord injury. Heatmap is not 
applicable on able-bodied controls compared to 12 months 
after spinal cord injury, since it is measured independently 
of 1, 3 and 12 months after injury. Values are z-scores, and 
n=7 (except PolyUb63 n=6) 
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4.3 THE ROLE OF FOXO PROTEINS IN SKELETAL MUSCLE METABOLISM. 
Spinal cord injury leads to decreased total protein content of FOXO3, and decreased 
phosphorylation of FOXO1 (Fig. 3B and 3D, study III). This raises the possibility that the 
metabolic derangements observed in spinal cord injured individuals could partly be explained 
by altered transcription of metabolic genes in addition to the decreased skeletal muscle mass. 
To further investigate the effects of FOXO proteins on the metabolism of skeletal muscle, we 
electroporated tibialis anterior muscle with a plasmid containing either FOXO1 modified to 
lack its transactivation domain (FOXO1dn), similarly modified FOXO3 protein (FOXO3dn) 
or empty control vector (Fig. 21). The FOXOdn constructs lacking the transactivation domain 
bind to the DNA, and compete out endogenous FOXO or other transcription factors proximal 
to the binding site, leading to inhibition of gene transcription. Each animal received FOXOdn 
construct or control vector in the contralateral leg. Glucose uptake, insulin stimulated 
transcriptome profile, and signaling proteins were analyzed 7 days after transfection. 
  
Deleted Region
DNA 
binding
FOXO3
Deleted Region
DNA 
binding
Transactivation domain
Figure 21. Schematic of FOXO1dn and FOXO3dn constructs showing, DNA binding domain, nuclear localization 
signal (NLS), and transactivation domain. Single amino acid alignment is shown below, with * indicating identical 
residues, : indicates strongly similar residues, and . weakly similar residues. Overall similarity between constructs 
was 58%. 
FOXO1
Deleted Region
DNA 
binding
FOXO3
Deleted Region
DNA 
binding
Transactivation domain
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Figure 22. FOXO1dn and FOXO3dn transfection overexpression of FOXOdn protein.  2DOG uptake in tibialis 
anterior muscle in control leg and FOXOdn transfected leg. Data are mean with individual fold changes for paired 
muscle samples overlayed. n=12 mice per construct, *p<0.05, and **p<0.01. 
Electroporation lead to efficient overexpression of both FOXOdn constructs, and decreased 
glucose uptake by 35% for FOXO1dn transfection and 20% for FOXO3dn transfection, 
indicating that FOXO1 and FOXO3 binding sites are involved in the regulation of glucose 
uptake in skeletal muscle (Fig. 22). The decrease in glucose uptake is partly explained by the 
decreased GLUT4 protein content (Fig. 23). 
While the decrease in GLUT4 protein content after FOXO1dn transfection was larger 
(40%), the decrease after FOXO3dn transfection was modest (10%). This led us to investigate 
whether additional mechanisms could be involved in the FOXOdn induced changes in glucose 
uptake. Thus, we performed a transcriptomic analysis of skeletal muscle from a subset of mice. 
 
    
Control
FOXO1dn
FOXO3dn
Figure 23. GLUT4 protein content in tibialis anterior of mice 
electroporated with either empty vector (open bars), FOXO1dn 
(gray bar), or FOXO3dn (striped bar). Data are mean ± SEM for 
paired muscle samples. n=12 mice per construct, *p<0.05. 
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Gene set enrichment analysis revealed several gene 
sets to be enriched by either construct. The overlap of 
affected gene sets between FOXO1dn and FOXO3dn 
was large, with 20 pathways being affected by both 
constructs, and 9 unique gene sets for FOXO1dn and 
3 unique gene sets for FOXO3dn (Fig. 24). This 
indicates that FOXO1 and FOXO3 binding sites have 
similar physiological functions. 
Among the gene sets enriched after FOXO1dn and 
FOXO3dn transfection were pathways involved in 
inflammation and oxidative phosphorylation (Fig. 25). 
Protein content of oxidative phosphorylation complex 
IV and V were downregulated by FOXO1dn 
transfection, while complexes II, III and IV, were 
downregulated by FOXO3dn transfection (Fig. 26). 
 
  
Figure 25. Gene sets enriched after FOXO1dn or FOXO3dn transfection. n=6 mice, all indicated pathways are 
significant at FDR<0.05. 
Figure 24. Overlap of gene sets enriched after FOXO1dn or 
FOXO3dn transfection. n=6. 
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Together, these data indicate that FOXO1 and FOXO3 binding sites regulate mitochondrial 
gene expression in addition to GLUT4, and suggest that these two mechanisms are synergistic 
in affecting glucose uptake. Interestingly, genes encoding for mitochondrial protein complexes 
have dual origin both from the nucleus and the mitochondrial DNA. The transcription factor 
responsible for mitochondrial genome regulation, Tfam, was not affected by FOXOdn 
transfection (data not shown), indicating that either FOXO1 and FOXO3 binding sites are 
directly regulating nuclear genes encoding mitochondrial complex proteins, or that FOXO1 
and FOXO3 binding sites affect other transcription factors involved in mitochondrial protein 
regulation. 
The gene set enrichment analysis also indicated that inflammatory pathways are affected by 
FOXOdn transfection. This was validated by studying STAT1 protein content and 
phosphorylation, along with gene expression of chemokines and inflammatory cell markers 
after FOXOdn transfection. We detect a large increase in total STAT1 protein content by both 
FOXO1dn and FOXO3dn transfection, and increased STAT1 phosphorylation by FOXO1dn 
transfection. Furthermore, we detected increased expression of myokines Ccl2, Ccl7, Ccl8 and 
Cxcl9, and increased expression of several inflammatory cells markers (Fig. 27). 
The increased STAT1 protein content suggests that FOXO1 and FOXO3 binding sites are 
involved in regulation of anti-inflammatory signaling cascades. Furthermore, the increased 
expression of chemokines and inflammatory cell markers implicate increased skeletal muscle 
infiltration of inflammatory cells. Interestingly, we do not detect changes in glucose uptake 
after transfecting FOXO1dn and FOXO3dn into undifferentiated C2C12 myoblasts (Fig. 28). 
Although this suggests that systemic inflammation is a necessary factor for the observed effects 
of FOXOdn constructs, the absent expression of GLUT4 in myoblasts casts a doubt on this 
interpretation. 
C F1 C F1 C F3 C F3
C-I
C-II
C-III
C-IV
C-V
Figure 26. Protein content of complex I-V after FOXO1dn or FOXO3dn transfection. Data are mean ± SEM. n=11 
mice, *p<0.05, and **p<0.01. 
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In summary, the decrease glucose uptake, and 
glucose handling enzymes, as well as the 
increased inflammatory markers after FOXOdn 
transfection, indicate that FOXO1 and FOXO3 
binding sites regulate skeletal muscle metabolism 
and inflammatory responses. Physical inactivity 
leads to changes in FOXO signaling, and skeletal 
muscle inflammation [128], raising the possibility 
that both are connected through the FOXO1 and 
FOXO3 transcription factors. Additionally, 
FOXO proteins regulate transcription of several 
antioxidant genes, suggesting that FOXO, 
inflammation and reactive oxygen species might 
together play a role in muscle homeostasis and 
plasticity. 
   
Figure 27. Protein content and phosphorylation of STAT1, 
and expression of chemokines, and inflammatory markers 
after FOXO1dn transfection (gray bars), or FOXO3dn 
transfection (striped bars). Data are mean ± SEM. n=11 mice. 
*p<0.05, and **p<0.01 
Figure 28. C2C12 myoblast basal and insulin stimulated glucose uptake after FOXO1dn (gray bars), 
and FOXO3dn (striped bars) transfection. Inset shows representative transfection with control, 
FOXO1dn or FOXO3dn plasmid. n=5 independent experiments. 
Transfection
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5 Study limitations 
 
There are a number of limitations with the studies presented here, some of which are 
inherent and some that are practical. The size of the cohorts in study I-III are rather small. We 
attempted to amend this by performing paired analyses where possible. In study I we utilized 
a crossover design where the same volunteers received both control and NAC infusion, and 
the spinal cord injured subjects in study II and study III donated biopsies several times over a 
year (with the exception of chronic spinal cord injured individuals and able-bodied controls). 
 
Another limitation is how to measure biological processes and signaling. As biological 
processes are both multistep and dynamic it is challenging to establish a macroscopic 
phenomenon by the instantaneous measurement of a smaller part. One way to establish 
concerted changes in signaling (eg. Akt signaling) is to measure several downstream targets 
instead of the protein per se. 
 
The microarray technology utilized in study IV has some technical limitation. One major 
limitation is determining whether a transcript is present or not. While there are methods to do 
this, they are prone to nucleotide sequence bias and are thus limited. We attempted to solve 
this problem through 2 different methods: cross validation through PCR (where all 
transcriptomic predicted changes were validated, data not shown), and by basing our 
conclusions on systems biology (mainly gene set enrichment analysis) instead of single gene 
measurements. 
 
A major consideration for understanding biology is the usage of male, isogenic mouse 
lines. Firstly, the bigger complication is the species rather than gender. As female mice have a 
four day estrous cycle, experiments performed one day might be different on another due to 
hormonal variation (especially when studying transcription factors). One can ask how 
valuable these conclusions are if they cannot stand up to such variation, but since we are not 
intending to directly develop pharmaceuticals but rather establish phenomena this is less of an 
issue. Whether research performed on mice translates to humans is a more challenging 
question to answer. The current number of RefSeq validated genes stands at 23 911 for mice, 
and 18 247 in humans, and around 70% of human and mouse genes are orthologous [129], 
indicating that to some extent, mouse genetic biology is comparable to human. Moreover, 
there is great value in studying a processes in a biological context instead of in isolation as for 
example in a tube. Most importantly, interventions possible in mice are not even remotely 
ethical in human. Thus mice experiments, although limited are still of great value.  
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6 SUMMARY AND CONCLUSIONS 
In study I we investigated the effects of antioxidant treatment on exercise-induced 
improvements on glucose handling. We found that antioxidant infusion before exercise 
hindered the beneficial effects of exercise on whole-body insulin signaling without affecting 
the canonical signaling cascades. This indicates that reactive oxygen species are involved in 
either signaling regulation at the level of insulin receptor, and/or on tissues other than skeletal 
muscle.  
In study II we investigated the changes occurring after spinal cord injury in terms AMPK 
signaling, subunit composition, fiber type distribution, and energy metabolism enzymes. We 
found that spinal cord injury induces decreased AMPK signaling, changed subunit 
composition, fiber type distribution, and reduced potential for oxidative metabolism. This 
suggests that AMPK signaling plays a role on skeletal muscle mass regulation in humans after 
spinal cord injury. 
In study III we continued our exploration of the effects of spinal cord injury on skeletal 
muscle health, by attempting to unravel the mechanisms underpinning decreased muscle mass. 
We found that proteasomal degradation is increased early in spinal cord injury, and continues 
to be high after 12 months, while translation and autophagy were transiently increased during 
the first year.  
Finally in Study IV, we are investigated the metabolic effects of the FOXO transcription 
factor binding sites, a protein whose signaling is increased by spinal cord injury. We found that 
FOXO transcription factor binding sites regulate glucose handling, oxidative phosphorylation 
enzymes, and GLUT4. One additional and unexpected finding, was that FOXO proteins 
appeared to be involved in regulation of skeletal muscle inflammation. Together these finding 
are furthering our understanding of how skeletal muscle regulates glucose uptake, and how the 
interface between inflammation and energy metabolism is involved in health. FOXO proteins 
are regulated by skeletal muscle disuse, AMPK, and reactive oxygen species, potentially 
connecting these processes in one unified transcriptional adaptation. 
Collectively, these studies are provide insight into mechanisms controlling several different 
aspects of skeletal muscle plasticity. This thesis work has partly resolved skeletal muscle 
adaptations to spinal cord injury-induced disuse, transcription factor mediated regulation of 
skeletal muscle glucose uptake, and the role of reactive oxygen species in skeletal muscle 
adaptions to exercise. 
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7 FUTURE PERSPECTIVE AND CLINICAL IMPLICATIONS 
The future of our health looks both bright and bleak. As the human population becomes 
increasingly sedentary, obese, and unhealthy, the need to understand our wellbeing becomes 
increasingly acute. At the same time, science has never had as many participants, resources and 
actionable conclusions. One of these insights is that human health is a multifactorial affair, 
where skeletal muscle plays an important role. In this thesis I have tried to further elucidate 
how skeletal muscle is involved in health by studying several complementary skeletal muscle 
processes.  
The findings in study I, show that reactive oxygen species are beneficial for insulin 
signaling.  One unexplored potential of this finding is the possibility of creating therapies based 
on generation of reactive oxygen species instead of inhibition. Of course this would have to be 
finally tuned in terms of when and where in the cell they are generated. Furthermore, these 
findings highlight the value of preventative lifestyle interventions, as both obesity and high 
sugar consumption are linked to increased reactive oxygen species generation. 
The findings in study II and study III are not just relevant for the fairly rare but debilitating 
results of spinal cord injury, but inform to some extent the effects of our how our sedentary 
behavior induces disuse atrophy and impaired skeletal muscle metabolism. The decreased 
AMPK signaling is potentially indicative of reduced ability to respond to stress and adaptations 
to low energy flux, while the decreased oxidative capacity is indicative of cellular damage. It 
is tempting to speculate on the potential beneficial effects of AMPK activation through 
pharmacological intervention in spinal cord injury, and in extension on sedentary behavior. 
Study III highlights targets for pharmacological interventions on skeletal muscle atrophy, by 
suggesting that proteasomal degradation is the most important target for intervention. 
Moreover, both these studies highlight the importance of early interventions after spinal cord 
injury. 
Study I, II and III are also informative for a condition that is currently distant, but 
becoming tantalizingly near: wide spread human space travel. The microgravity environment 
of space induces both muscle atrophy through unloading, and has oxidative properties due to 
solar and cosmic winds [130]. Understanding the interplay of protein synthesis and 
degradation, with energy metabolism and reactive oxygen species will enable us to better 
understand the challenges of this new environment. 
As both insulin resistance and skeletal muscle atrophy involve changes in FOXO signaling, 
Study IV proposes a mechanism for integrating inflammatory and energy signaling, with 
obesity and sedentary behavior. Since FOXO signaling plays a multitude of roles, direct 
modulation of FOXO signaling seems farfetched. Elucidating the gene networks controlled by 
FOXO transcription factors improves our understanding on how skeletal muscle metabolism is 
affected during disuse atrophy. 
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